Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report

Abstract

Drug-induced bullous pemphigoid (BP) has added to an increasing association with dipeptidyl-peptidase-4 inhibitors (DPP4i). Among various DPP4i used for the treatment of diabetes, omarigliptin is an once-weekly oral agent that received the first global approval in Japan and widely used in anti-diabetic algorithm; however, reports only implicate a potential risk for developing BP comparable with other DPP4i. 1 We report, to our knowledge, the first case of BP receiving omarigliptin, whose serum IgG targets BP180-NC16a.A 65-year-old Japanese man presented a 6-month history of itchy blisters on the face and trunk. Combined with preceded mitiglinide calcium hydrate voglibose, he had received once-weekly DPP4i omarigliptin for diabetes 30 months before. Examination showed fingertipsized tense blisters and erosions on his face and back (Figure 1A, B).This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.